ArticleScientific reports2025
Neuroprotective effect of Tozasertib in Streptozotocin-induced alzheimer's mice model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Feasibility Study of Nose-to-Brain Delivery of Galantamine for Alzheimer's Disease: Enhancing Olfactory-Region Deposition to Improve Therapeutic Efficacy.Pharmaceutics · 2026Article
- A Combination of Artemisinin, N-acetylcysteine, Resveratrol, and Hesperidin Ameliorates Hippocampal Damage and Pathological Features in an Experimental Model of Alzheimer's Disease.Neurochemical research · 2026Article
- A sustained-release depot formulation of β-nicotinamide mononucleotide for alleviating chemotherapy-induced myelosuppression.Materials today. Bio · 2026Article
- Reversal of diabetes-associated cognitive impairment through modulation of BDNF, insulin, and NF-κB pathways by a marketed herbal formulation.3 Biotech · 2026Article
- Lenalidomide ameliorates cognitive impairment via putative AChE inhibition: an in silico and in vivo study in a scopolamine-induced cognitive impairment model.Scientific reports · 2026Article
- Neuroprotective effects of Urolithin A and B in an intracerebroventricular streptozotocin-induced Alzheimer's-like model in rats.BMC pharmacology & toxicology · 2026Article
- Article
- Bifunctional BODIPY-Clioquinol Copper Chelator with Multiple Anti-AD Properties.International journal of molecular sciences · 2025Article
- Article
- Resveratrol Analogs Ameliorate Mitochondrial Impairment and Insulin Resistance in a Streptozotocin-Induced In Vitro Model of Alzheimer's Disease.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is responsible for more than 80% of cases of dementia in senior individuals globally. In the current study, the role of modulation of the FGF1/PI3K/Akt pathway in the protective effect of tozasertib was evaluated. Experimental dementia was induced in mice by injecting streptozotocin (STZ) intracerebroventricularly. Various biochemical parameters for oxidative stress & lipid peroxidation (SOD, GSH, catalase, TBARS), neuroinflammation (MPO, IL-6, IL-1 β, TNF-α, NFκB), apoptotic markers (Bax, Bcl-2, Caspase-3), and memory parameters (AChE activity, β1-40 levels) were assessed. The behavioral parameters evaluated included the Morris Water Maze test and the step-down passive avoidance test. Histological changes were assessed using H&E staining. ICV STZ-induced AD resulted in increased oxidative stress, lipid peroxidation, neuroinflammation, apoptosis, and decreased learning and memory. The results showed that administration of tozasertib improved memory, decreased levels of oxidative stress, inflammatory parameters, and apoptotic markers, and improved histological parameters in a dose-dependent manner. Pre-administration of LY294002, a PI3K/Akt pathway inhibitor, partially reversed the protective effects of Tozasertib, suggesting possible involvement of this pathway. However, as the mechanism was inferred primarily through pharmacological antagonism, further studies including direct molecular assessments (e.g. p-Akt/t-Akt) are warranted to confirm the role of FGF1/PI3K/Akt signaling in Tozasertib's action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.